We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Prenatal Testing May Also Detect Some Maternal Cancers

By LabMedica International staff writers
Posted on 02 Aug 2015
A new bioinformatics study shows that prenatal genetic test results, such as revealed by noninvasive prenatal testing (NIPT) for fetal chromosome abnormalities, may also detect underlying conditions in the mother, including cancer. More...


Diagnosis of cancer during pregnancy is relatively uncommon (incidence about 1 in 1,000 women). A team of scientists and clinicians, led by Diana W. Bianchi, MD, of Tufts Medical Center (Boston, MA, USA) and the Reproductive and Genetic Health Expert Advisory Panel at Illumina (Redwood City, CA, USA), has reported results of their genome-wide analysis performed on available DNA sequencing data for a case series of 8 women with abnormal NIPT results. Analysis showed discordance with the fetal karyotype: while their fetuses had normal chromosomes, retrospective genomic analysis showed that the abnormal results were due to a variety of undiagnosed cancers in the mothers. The findings demonstrate that previously undetected maternal cancers may provide a biological explanation for some differences between results from prenatal diagnostic versus prenatal screening tests.

NIPT is a recent clinical advance that provides pregnant women with information about possible chromosomal abnormalities, such as Down syndrome, in their fetuses. The screening test, which can be offered as early as the 10th week of pregnancy, analyzes fragments of placental and maternal DNA that circulate in maternal plasma. In women with cancer, the plasma sample also contains cancer DNA.

“This study provides one explanation for when NIPT results are different from the fetal karyotype. It highlights the need to perform a diagnostic procedure to determine true fetal karyotype whenever NIPT suggests chromosomal abnormalities,” said Dr. Bianchi, expert on NIPT.

The 8 cases in this preliminary study of occult malignancy came from 125,426 samples submitted from asymptomatic pregnant women who underwent NIPT for fetal chromosomal abnormalities, of which 3757 cases were positive for one or more abnormalities in the number of chromosomes 13, 18, 21, X, or Y. The women’s physicians later reported 10 cases of cancer to the laboratory that originally conducted the NIPT, the study analyzed 8 of these in depth. All of the women had abnormal NIPT results, and most frequently, more than one chromosomal abnormality was detected, a very unusual result. Cancer was diagnosed during pregnancy or postpartum in these women at an average of 16 weeks following the initial NIPT. The clinical importance of these findings will require further research.

“NIPT results may lead to findings of an underlying maternal condition, which, in these cases, was due to cancer,” said Dr. Bianchi, “The take-home message is that women should be aware of this possibility when they seek testing. More research needs to be done to further study this occurrence to help guide physicians on how to counsel women and manage their follow-up care.”

The study, by Bianchi DW, et al, was published July 14, 2015, in the Journal of the American Medical Association (JAMA).

Related Links:

Tufts Medical Center
Illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
All-in-One Molecular System
AIO M160
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.